Research ArticleResearchMedication Safety

Long-term COMBI-I follow-up favored spartalizumab, with more severe adverse events

Journal of clinical oncology : official journal of the American Society of Clinical Oncology (PubMed)Sep 10, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

Final COMBI-I follow-up found longer overall survival with spartalizumab added to dabrafenib and trametinib in BRAF V600-mutant advanced melanoma, although the trial had previously failed its primary progression-free-survival endpoint and severe treatment-related events were more common with the three-drug regimen.

What NurseJet pulled from the source

Among 532 randomized patients followed for a median 76.9 months, median overall survival was 61.5 months with spartalizumab plus dabrafenib and trametinib versus 41.6 months with placebo plus dabrafenib and trametinib (hazard ratio 0.760, 95% CI 0.598 to 0.966).

Why this matters for nurses

The survival signal is clinically important, but nurses should read it alongside the failed primary endpoint and the higher treatment-related toxicity burden rather than interpreting the final analysis as uncomplicated superiority.

Bedside takeaway

Pair the long-term survival signal with the failed primary endpoint and the higher severe-toxicity burden.

Key takeaways

The original 24-month analysis did not meet the trial's primary progression-free-survival endpoint.
Pyrexia was the most common treatment-related adverse event, reported in 65.9% with spartalizumab and 46.2% with placebo.
Grade 3 or higher treatment-related adverse events occurred in 57.3% versus 36.7%, respectively.

Practice implications

For patients receiving these therapies, monitor and escalate fever and other treatment toxicities according to the oncology regimen, provider orders, and local protocol.

Limitations & cautions

Abstract-only summary. This is a final secondary overall-survival analysis after the trial failed its primary progression-free-survival endpoint; the abstract provides limited detail on individual serious toxicities or subsequent therapy.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology (PubMed)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology (PubMed). COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42585631/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Internal and emergency medicine (PubMed)Oct 20, 2026Research Article

A multicenter triple-blind randomized controlled trial of 73 emergency department patients found intravenous ibuprofen (800 mg) produced significantly greater pain score reductions at 10 and 30 minutes and shorter ED stays compared with intravenous ketorolac (30 mg).

Emergency Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyWorkflowAI summary · original source linked below

Acute low back pain (LBP) accounts for high emergency department utilization, yet clinicians continually seek non-opioid parenteral analgesics that provide rapid, dependable relief without prohibitive adverse profiles. In this multicenter, triple-blind randomized clinical trial conducted across three academic hospital emergency departments, 73 adult patients presenting with acute LBP were randomized to receive either intravenous ibuprofen (800 mg, n=34) or intravenous ketorolac (30 mg, n=39). Analgesic infusions were prepared in quadruplicate blocks by trained head nurses, maintaining blinding for patients, investigators, and biostatisticians. Pain was recorded on a 100-mm Visual Analog Scale (VAS) at baseline, 10 minutes, and 30 minutes post-infusion. Mean VAS pain scores were significantly lower in the ibuprofen arm at 10 minutes (49.6 vs 57.4; p = 0.013) and at 30 minutes (32.2 vs 40.7; p = 0.038). Furthermore, 70.6% of ibuprofen patients achieved mild pain levels by 30 minutes versus 35.9% of ketorolac recipients (p < 0.001). Mean ED length of stay was also significantly shorter in the ibuprofen cohort, while rescue analgesia requirements and drug-related adverse events did not differ between arms.

Key takeaways

Multicenter triple-blind RCT randomized 73 ED patients with acute low back pain to IV ibuprofen 800 mg (n=34) or IV ketorolac 30 mg (n=39).
IV ibuprofen yielded significantly lower VAS pain scores at both 10 minutes (49.6 vs 57.4, p = 0.013) and 30 minutes (32.2 vs 40.7, p = 0.038).
Twice as many patients achieved mild pain intensity at 30 minutes with ibuprofen compared to ketorolac (70.6% vs 35.9%, p < 0.001).
Mean ED length of stay was significantly reduced in the ibuprofen cohort, without any increase in adverse drug events or rescue analgesia.
Findings support IV ibuprofen as an effective, rapid-acting, non-opioid parenteral alternative to ketorolac for acute musculoskeletal back pain in the ED.

Why this matters on shift

Emergency nurses manage acute musculoskeletal back pain daily and frequently administer IV NSAIDs to avoid opioid exposure. Ketorolac has traditionally served as the default parenteral non-opioid, but these triple-blind findings show IV ibuprofen (800 mg) delivers faster and deeper pain reduction within the critical first 30 minutes, doubles the rate of relief down to mild pain, and facilitates earlier discharge without added complications.

Bedside takeaway

In a triple-blind ED RCT of 73 adults with acute low back pain, IV ibuprofen (800 mg) achieved lower VAS pain scores at 10 and 30 minutes and higher mild-pain rates (70.6% vs 35.9%) than IV ketorolac (30 mg).

Nursing implications

Verify renal function, volume status, GI bleeding history, and pregnancy status prior to parenteral NSAID infusion; administer IV ibuprofen over the ordered infusion time and evaluate pain response using a standardized scale at 10 and 30 minutes to determine if rescue analgesia is needed.

Limitations & cautions

Modest total sample size (73 patients) across three university centers; evaluation period concluded at 30 minutes without tracking long-term recurrence or post-discharge outcomes.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Internal and emergency medicine (PubMed). Intravenous ibuprofen versus ketorolac for acute low back pain in the emergency department: a triple-blind randomized clinical trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of the American College of Cardiology (PubMed)Oct 13, 2026Research Article

The multicenter SUBCUT-HF II randomized trial of 172 hospitalized heart failure patients demonstrated that early discharge using a wearable subcutaneous furosemide minipump achieved 4.0 more days alive and out of hospital at 30 days compared with standard inpatient care.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementWorkflowAI summary · original source linked below

Patients hospitalized with decompensated heart failure frequently endure prolonged inpatient admissions solely to finish intravenous loop diuretic titration. In the multicenter, open-label, active-controlled SUBCUT-HF II randomized trial (NCT05419115) conducted across the United Kingdom, 172 patients hospitalized for heart failure who required continued parenteral diuretic therapy were randomized to an early supported discharge strategy (n=92) or usual inpatient care (n=80). The early discharge cohort received a novel pH-neutral formulation of subcutaneous furosemide administered via a wearable, patient-operated minipump, supported by outpatient clinical reviews every 3 days during active infusion, alongside a 2-week follow-up for both arms. The primary endpoint of days alive and out of hospital (DAOH) at 30 days was significantly higher in the early discharge arm (4.0 more days, 95% CI: 2.1–5.8 days; p < 0.001). Mean index hospital stay was shortened by 5.5 days (95% CI: 3.6–7.4 days; p < 0.001). This DAOH benefit was sustained through 60 days (4.2 days, 95% CI: 0.9–7.6 days), despite non-statistically significant higher heart failure readmissions in the early discharge group (14% [n=13] vs 6% [n=5]; OR: 2.45, 95% CI: 0.81–7.43). Serious adverse events occurred in 25% vs 23% of participants, and device issues arose in 3% of placements without serious sequelae.

Key takeaways

Multicenter UK randomized controlled trial (SUBCUT-HF II) evaluated 172 patients hospitalized with heart failure requiring ongoing parenteral diuresis.
Early discharge with a wearable subcutaneous furosemide minipump yielded 4.0 more days alive and out of hospital at 30 days (p < 0.001).
Mean length of index hospital stay decreased by 5.5 days (95% CI: 3.6–7.4 days, p < 0.001) in the subcutaneous minipump cohort.
Clinical benefits persisted at 60 days (4.2 additional DAOH), with comparable serious adverse event rates (25% vs 23%).
Device-related technical issues were observed in only 3% of placements, confirming the mechanical feasibility of outpatient wearable infusion.

Why this matters on shift

Cardiology and telemetry nurses spend extensive time coordinating intravenous diuretic administration, monitoring fluid balances, and planning discharge for heart failure patients who are otherwise clinically stable. Wearable subcutaneous infusion technology enables safe, out-of-hospital decongestion, liberating acute hospital beds and improving patient quality of life, but requires specialized nurse education on pump operation, infusion site care, and vigilant outpatient symptom surveillance.

Bedside takeaway

In the 172-patient SUBCUT-HF II trial, early discharge with a wearable subcutaneous furosemide minipump yielded 4.0 more days alive and out of hospital at 30 days and shortened index hospital stay by 5.5 days.

Nursing implications

Educate heart failure patients on subcutaneous minipump placement, needle insertion site inspection for local erythema or leakage, daily weights, and symptom red flags; coordinate close outpatient follow-up checks every 3 days during active subcutaneous loop diuretic titration.

Limitations & cautions

Open-label trial design; trend toward higher 30-day readmissions (14% vs 6%, OR 2.45) warrants close outpatient monitoring systems; conducted within UK National Health Service infrastructure.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of the American College of Cardiology (PubMed). Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Nursing open (PubMed)Oct 1, 2026Research Article

An exploratory randomized clinical trial of 192 cancer patients receiving standardized nurse-led care for totally implantable venous access devices found complication rates were uniformly low across 10 mL saline, 20 mL saline, and heparin lock flushing arms.

Oncology Med-SurgAI summaryReview source

Research ArticleResearchWorkflowQuality ImprovementAI summary · original source linked below

Oncology clinicians continue to debate whether regular heparin locking remains necessary to prevent catheter occlusions in totally implantable venous access devices (TIVADs) or whether normal saline flushes provide adequate patency. In this single-center, prospective, exploratory, single-blind randomized trial conducted in Taiwan (NCT05707936), 192 oncology patients with TIVADs were randomized into three flushing groups: 10 mL normal saline, 20 mL normal saline, or heparin lock (100 units/mL), all delivered within a standardized, protocol-driven, nurse-led catheter care framework. Catheter-related complications were rare across the entire cohort. Only one catheter occlusion occurred (in the 10 mL saline group), while zero occlusions developed in either the 20 mL saline or heparin lock groups. Minor bleeding occurred in three participants, and zero catheter-related bloodstream infections (CRBSIs) or severe adverse events were observed. The exceptionally low complication incidence across all groups precluded definitive statistical non-inferiority conclusions, indicating that standardized nursing competency and strict technique, rather than locking solution alone, drive catheter safety.

Key takeaways

Prospective 3-arm exploratory RCT randomized 192 adult oncology patients with implantable ports to 10 mL saline, 20 mL saline, or heparin lock.
Complication rates were uniformly low under a structured, nurse-led catheter management protocol.
Only one catheter occlusion occurred across all 192 patients (10 mL saline arm), with zero occlusions in the 20 mL saline and heparin groups.
No catheter-related bloodstream infections (CRBSIs) or severe device adverse events occurred in any study arm.
Authors emphasized that standardized nursing care protocols and strict adherence are paramount, while larger trials are needed before omitting heparin.

Why this matters on shift

Oncology and infusion nurses access and de-access implanted venous ports constantly throughout chemotherapy regimens. Omitting heparin locks would simplify nursing workflow, avoid heparin-induced thrombocytopenia risks, and cut medication costs; however, this trial underscores that protocol adherence, pulsatile flushing technique, and positive pressure de-access by trained nurses maintain high patency and low infection rates regardless of flush volume.

Bedside takeaway

In a 192-patient oncology trial of totally implantable ports managed by trained nurses, complications were rare across 10 mL saline, 20 mL saline, and heparin groups (1 occlusion, 0 CRBSIs, 3 minor bleeds).

Nursing implications

Adhere strictly to standardized, aseptic catheter access protocols; use vigorous pulsatile flushing and positive-pressure clamp sequences; do not abandon institutional heparin locking protocols until supported by definitive phase 3 non-inferiority data.

Limitations & cautions

Single-center exploratory design; low event rates precluded statistically powered comparative non-inferiority inferences between saline volumes and heparin locks.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Nursing open (PubMed). Flushing Strategies for Totally Implantable Venous Access Devices in Nurse-Led Cancer Care: Exploratory Randomized Clinical Trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Triple-blind randomized trial of 73 ED patients finds intravenous ibuprofen achieves superior acute pain relief compared with ketorolac for acute low back pain

Multicenter trial of 172 hospitalized heart failure patients finds wearable subcutaneous furosemide minipump strategy adds 4.0 days alive and out of hospital at 30 days

Exploratory randomized trial of 192 cancer patients demonstrates uniformly low catheter complications under standardized nurse-led port flushing protocols